SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-025941
Filing Date
2024-02-07
Accepted
2024-02-07 07:59:02
Documents
16
Period of Report
2024-02-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d678628d8k.htm   iXBRL 8-K 27123
2 EX-99.1 d678628dex991.htm EX-99.1 15451
6 GRAPHIC g678628g0207083653209.jpg GRAPHIC 2957
  Complete submission text file 0001193125-24-025941.txt   179849

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20240207.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20240207_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20240207_pre.xml EX-101.PRE 11712
17 EXTRACTED XBRL INSTANCE DOCUMENT d678628d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 24602222
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)